Skip to content

Sleep, fatigue, and cognition

TL;DR — Moldofsky's 1975–76 experiments founded the "non-restorative sleep" theory of fibromyalgia: alpha rhythms intruding into NREM sleep in "fibrositis" patients, and slow-wave-sleep (SWS) deprivation inducing tenderness and musculoskeletal symptoms in healthy volunteers. Replication was partial at best — Lentz reproduced the pain-threshold drop (24%) without producing the alpha-EEG pattern, and Older found no threshold change at all — so alpha-delta intrusion is neither necessary nor sufficient. Modern meta-analytic polysomnography shows real but moderate objective abnormalities (less total and slow-wave sleep, more wake after sleep onset; Hedges g 0.5–0.8) alongside much larger subjective complaints (PSQI g ≈ 2.2). The strongest causal-direction evidence is longitudinal: poor/nonrestorative sleep prospectively predicts new-onset fibromyalgia and widespread pain in four independent cohorts (RR up to 3.4, dose-dependent), and within patients sleep predicts next-year pain, not the reverse. "Fibrofog" is objectively measurable — deficits across memory, inhibitory control, and processing speed with moderate effect sizes (g 0.3–0.6) — but subjective complaint (≈84% of patients) exceeds objective impairment, and depression, physical function, and comorbidity account for much of the gap.

The Moldofsky experiments: origin of the non-restorative sleep hypothesis

  • Observation arm: overnight EEG in patients with "fibrositis syndrome" showed anomalous alpha rhythms superimposed on NREM (delta) sleep — "alpha-delta sleep." In parallel, healthy subjects deprived of stage 4 sleep developed temporary musculoskeletal and mood symptoms comparable to patients'. Moldofsky proposed "fibrositis" be considered a non-restorative sleep syndrome, with an internal arousal mechanism impairing the restorative function of NREM sleep, possibly serotonin-mediated (Moldofsky 1975, PMID 169541).
  • Induction arm: 6 healthy volunteers deprived of stage 4 sleep developed more musculoskeletal symptoms and a significant increase in muscle tenderness; 7 REM-deprived controls did not (Moldofsky & Scarisbrick 1976, PMID 176677). This was the first experimental production of an FM-like phenotype in healthy humans — with n=6.

Later replications: partial and failed

Study Design Result
Older 1998 (PMID 9632083) 13 healthy volunteers, 3 nights of delta-wave sleep interruption (DWSI) vs 6 non-deprived controls; dolorimetry + IGF-1 No significant change in pain thresholds vs controls; symptom increase driven by fatigue, not pain; serum IGF-1 unchanged. Direct failure to replicate the tenderness induction
Lentz 1999 (PMID 10405949) 12 healthy sedentary middle-aged women, 3 nights of selective SWS disruption (tone-induced, preserving total sleep time) 24% decrease in musculoskeletal pain threshold after night 3, plus fatigue and skin flare response — but the protocol did not evoke an alpha-EEG sleep pattern

Synthesis: SWS disruption can lower pain thresholds in some cohorts (Lentz's middle-aged sedentary women) but not others (Older's healthy volunteers), and symptom induction occurs without alpha-delta intrusion — dissociating the EEG marker from the symptom mechanism. Alpha-delta sleep is therefore best read as one nonspecific arousal signature, not the cause of FM. The historical importance of the model is that it made FM a disorder of CNS physiology decades before neuroimaging (see pathophysiology-central) and seeded serotonergic drug hypotheses.

Modern polysomnography: meta-analytic picture

Meta-analysis of 25 case-control studies (n=2,086) (Wu 2017, PMID 28545798):

Outcome (FM vs healthy controls) Effect size (Hedges g, 95% CI)
Wake time after sleep onset (PSG, 19 studies) +0.81 (0.21 to 1.41)
Total sleep time (PSG) −0.78 (−1.34 to −0.15)
Sleep efficiency (PSG) −0.78 (−1.23 to −0.32)
% stage 1 (light) sleep (PSG) +0.55 (0.15 to 0.95)
% slow-wave sleep (PSG) −0.66 (−1.21 to −0.12)
PSQI global score (subjective, 7 studies) +2.19 (1.58 to 2.79)
Subjective sleep-onset latency +1.75 (0.80 to 2.70)

Two conclusions: (1) objective sleep architecture is genuinely abnormal — shorter, lighter, more fragmented, SWS-depleted sleep; (2) the subjective-objective gap is large (g ≈ 2.2 vs ≈ 0.6–0.8), meaning perceived sleep quality is disproportionately poor — consistent with the same amplification seen in pain and cognition domains. Note the meta-analysis did not quantify alpha-delta intrusion, which lacks standardized scoring.

Sleep and pain: longitudinal, bidirectional evidence

Population-level prospective studies (exposure measured before outcome):

  • HUNT (Norway), 12,350 women free of FM and musculoskeletal pain at baseline, ~10-year follow-up: dose-dependent association between sleep problems and incident self-reported FM; adjusted RR 3.43 (95% CI 2.26–5.19) for "often/always" sleep problems, rising to 5.41 (2.65–11.05) in women ≥45 (Mork & Nilsen 2012, PMID 22081440).
  • UK ≥50 cohort (n=4,326, 3 years): nonrestorative sleep was the strongest independent predictor of new-onset widespread pain (ACR 1990 definition; OR 1.9, 95% CI 1.2–2.8), ahead of anxiety and cognitive complaint (McBeth 2014, PMID 24574238).
  • UK 25–65 cohort (n=3,171, 15 months): sleep problems predicted new CWP (OR 2.7, 95% CI 1.6–3.2), additive with somatic symptoms and illness behavior (combined 12× odds) (Gupta 2007, PMID 17085772).
  • Within diagnosed FM (n=600, 1-year follow-up, path analysis): baseline sleep predicted subsequent pain (β=0.13), pain predicted physical function, function predicted depression — and no variable predicted sleep, placing sleep upstream in the symptom cascade; 96% of the sample scored as problem sleepers (Bigatti 2008, PMID 18576297).

Directionality verdict: the poor-sleep→pain arrow has replicated prospective support; the pain→poor-sleep arrow is mechanistically obvious day-to-day but was not what emerged at 1-year resolution in FM (Bigatti 2008, PMID 18576297). This makes sleep the leading modifiable target for prevention trials that have not yet been run — see genetics-and-risk-factors for the full predictor table.

Fatigue — and how it differs from ME/CFS fatigue

Fatigue is near-universal in FM (92% among HCV-cohort FM cases, for one quantified example; Mohammad 2012, PMID 22499073) and is what SWS-deprivation induces most reliably in healthy subjects even when pain thresholds do not move (Older 1998, PMID 9632083).

The FM/ME-CFS boundary: - In a primary-care chronic fatigue sample, 70% had persistent diffuse musculoskeletal pain with tender-point exams similar to FM patients' — most patients meeting CFS criteria also met FM criteria (Goldenberg 1990, PMID 2317224). - Against the "single syndrome" reading, reviews cataloguing direct FM-vs-CFS comparisons document differences across multiple physiological and biomarker parameters, arguing that the underlying pathophysiologies differ (Abbi & Natelson 2013, PMID 22927538; Natelson 2019, PMID 30795933). - The post-infective fatigue phenotype (fatigue + musculoskeletal pain + neurocognitive difficulty) arises in ~12% after diverse infections, predicted by acute-illness severity (Hickie 2006, PMID 16950834) — a shared onset pathway for both syndromes. - Practical distinction used clinically: current ME/CFS case definitions (IOM 2015) require post-exertional malaise as a core feature (Clayton 2015, PMID 25668027), whereas FM criteria are anchored on widespread pain; where a patient sits often depends on which specialist they see. Quantified overlap and the boundary problem are treated in comorbidities-and-overlap.

"Fibrofog": objective neuropsychology vs subjective complaint

Objective findings

Meta-analysis of 37 studies (964 FM vs 1,025 age-matched controls) found significant deficits in every cognitive domain tested (Bell 2018, PMID 29388512):

Domain Effect size (g)
Inhibitory control 0.61 (largest)
Short-term memory 0.51
Long-term memory 0.50
Set shifting 0.30 (smallest)

Processing speed and other executive components (updating, accessing) were also significantly impaired (Bell 2018, PMID 29388512). These are moderate, real deficits — comparable in size to the objective sleep abnormalities, and the authors suggest routine cognitive screening may be warranted.

Subjective complaint exceeds objective deficit

  • 84% of 105 women with FM reported subjective cognitive complaints; complaints were most strongly associated with depression scores, everyday physical functioning, and working-memory performance, with the full model explaining only 32% of complaint variance (Gelonch 2017, PMID 28301977). Objective performance is thus one contributor among several to the felt severity of fibrofog.
  • New-onset widespread pain is itself predicted by prior cognitive complaint (OR 1.3, 95% CI 1.04–1.6) (McBeth 2014, PMID 24574238) — cognitive complaint may be part of the prodromal symptom-amplification phenotype rather than purely a consequence of pain.

Confounders: comorbidity and medication

  • Depression is the dominant measured confounder: current MDD point-prevalence in FM is ~25% (structured interviews) with lifetime prevalence 65% (Løge-Hagen 2019, PMID 30699852; see comorbidities-and-overlap), and depression scores track subjective complaint (Gelonch 2017, PMID 28301977). Bell's meta-analysis used age-matched controls but primary studies varied in controlling mood, pain, and sleep.
  • Poor sleep (above) plausibly mediates part of the cognitive deficit; formal mediation analyses at meta-analytic scale are lacking.
  • Centrally acting FM drugs (pregabalin, amitriptyline, opioids, benzodiazepines) plausibly depress measured cognitive performance, but no study isolating the medication contribution to fibrofog (medicated-vs-unmedicated comparison or washout design) was found in targeted PubMed searches (2026-08-28), and the meta-analytic base does not report an unmedicated estimate (Bell 2018, PMID 29388512). This is a documented evidence gap, not an established effect — an open question below.

Open questions

  • Does treating sleep (CBT-I, SWS-enhancing agents) in at-risk or early FM prevent or reverse widespread pain — the interventional test implied by four prospective cohorts (PMIDs: 22081440, 24574238, 17085772, 18576297)? No such prevention trial is cited in the sources reviewed here.
  • Is alpha-delta intrusion quantifiable in a standardized way, and does any PSG signature track symptom severity or treatment response, given symptom induction occurs without it (Lentz 1999, PMID 10405949)?
  • Why did stage-4 deprivation induce tenderness in Moldofsky's and Lentz's cohorts but not Older's (PMIDs: 176677, 10405949, 9632083) — sex, age, activity level, or protocol differences? A definitive, adequately powered SWS-disruption study has never been run.
  • How much of the fibrofog effect size (g 0.3–0.6; Bell 2018, PMID 29388512) survives adjustment for depression, sleep, and centrally acting medication? Requires individual-participant-data meta-analysis or a medication-naive cohort.
  • Do objective cognitive measures worsen, stabilize, or fluctuate with disease course, and do they respond to any FM treatment? Longitudinal neuropsych data are absent from the meta-analytic base (Bell 2018, PMID 29388512).

References

  1. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med. 1975;37(4):341-51. PMID 169541
  2. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med. 1976;38(1):35-44. PMID 176677
  3. Older SA, et al. The effects of delta wave sleep interruption on pain thresholds and fibromyalgia-like symptoms in healthy subjects; correlations with insulin-like growth factor I. J Rheumatol. 1998;25(6):1180-6. PMID 9632083
  4. Lentz MJ, et al. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol. 1999;26(7):1586-92. PMID 10405949
  5. Wu YL, et al. Sleep disturbances in fibromyalgia: a meta-analysis of case-control studies. J Psychosom Res. 2017;96:89-97. PMID 28545798
  6. Mork PJ, Nilsen TI. Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis Rheum. 2012;64(1):281-4. PMID 22081440
  7. McBeth J, et al. Predictors of new-onset widespread pain in older adults: results from a population-based prospective cohort study in the UK. Arthritis Rheumatol. 2014;66(3):757-67. PMID 24574238
  8. Gupta A, et al. The role of psychosocial factors in predicting the onset of chronic widespread pain: results from a prospective population-based study. Rheumatology (Oxford). 2007;46(4):666-71. PMID 17085772
  9. Bigatti SM, et al. Sleep disturbances in fibromyalgia syndrome: relationship to pain and depression. Arthritis Rheum. 2008;59(7):961-7. PMID 18576297
  10. Goldenberg DL, et al. High frequency of fibromyalgia in patients with chronic fatigue seen in a primary care practice. Arthritis Rheum. 1990;33(3):381-7. PMID 2317224
  11. Abbi B, Natelson BH. Is chronic fatigue syndrome the same illness as fibromyalgia: evaluating the 'single syndrome' hypothesis. QJM. 2013;106(1):3-9. PMID 22927538
  12. Natelson BH. Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia: definitions, similarities, and differences. Clin Ther. 2019;41(4):612-618. PMID 30795933
  13. Hickie I, et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575. PMID 16950834
  14. Bell T, et al. Meta-analysis of cognitive performance in fibromyalgia. J Clin Exp Neuropsychol. 2018;40(7):698-714. PMID 29388512
  15. Gelonch O, et al. Cognitive complaints in women with fibromyalgia: are they due to depression or to objective cognitive dysfunction? J Clin Exp Neuropsychol. 2017;39(10):1013-1025. PMID 28301977
  16. Løge-Hagen JS, et al. Prevalence of depressive disorder among patients with fibromyalgia: systematic review and meta-analysis. J Affect Disord. 2019;245:1098-1105. PMID 30699852
  17. Mohammad A, et al. Prevalence of fibromyalgia among patients with chronic hepatitis C infection. J Clin Gastroenterol. 2012;46(5):407-12. PMID 22499073
  18. Clayton EW. Beyond myalgic encephalomyelitis/chronic fatigue syndrome: an IOM report on redefining an illness. JAMA. 2015;313(11):1101-2. PMID 25668027